Grainne M. Kerr

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Journal: Nature
Published: July 02, 2025

Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Targeting the SHOC2-RAS interaction in RAS-mutant cancers.

Journal: Nature
Published: May 08, 2024

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.

Journal: Nature
Published: July 26, 2023

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.

Journal: Cancer research
Published: April 14, 2023

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.

Journal: Nature medicine
Published: March 08, 2022

Structure of the MRAS-SHOC2-PP1C phosphatase complex.

Structure of the MRAS-SHOC2-PP1C phosphatase complex.

Journal: Nature
Published: February 02, 2022

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.

Journal: Cell reports
Published: May 06, 2021

Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells.

Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells.

Journal: Molecular therapy. Methods & clinical development
Published: March 26, 2021

Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.

Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.

Journal: ACS pharmacology & translational science
Published: November 15, 2020

Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen.

Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen.

Journal: Scientific reports
Published: March 30, 2020

Irish Defence Forces combat medical technician training: experience of a novel university medical school-based programme.

Irish Defence Forces combat medical technician training: experience of a novel university medical school-based programme.

Journal: BMJ military health
Published: February 05, 2020

The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma.

The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma.

Journal: Molecular cancer therapeutics
Published: October 23, 2019
Showing 1-12 of 28

Last Updated: 09/26/2026